Clinical trial
Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)
NCT00300118 · Dr. Falk Pharma GmbH, Industry · Completed
Key facts
| NCT number | NCT00300118 |
|---|---|
| Title | Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD) |
| Official title | Double-blind, Double-dummy, Randomized, Multicentre Study to Compare the Efficacy and Safety of Oral Budesonide (9 mg) and Oral Mesalazine (4.5 g) in Moderately Active Crohn's Disease Patients |
| Lead sponsor | Dr. Falk Pharma GmbH, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Drug |
| Interventions | budesonide, mesalazine |
| Enrollment | 311 |
| Start date | Sep 1, 2004 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Mar 8, 2006 |
| Last update posted | May 19, 2014 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: